The Leukemia & Lymphoma Society (LLS) recently announced its commitment to fund an innovative and collaborative project called Beat AML. This pioneering cancer research initiative aims to develop a precision medicine approach to improve outcomes for patients with acute myeloid leukemia (AML).
Acute Myeloid Leukemia
Acute myeloid leukemia is a particularly devastating blood cancer, with less than 25% of newly diagnosed patients surviving beyond five years. Thousands of distinctive malformed genes cause AML, making each case almost as unique as each individual patient. Because of its genetic complexity, AML is difficult to treat. Patients are generally treated with a two-drug therapy, an approach that has remained relatively unchanged for over three decades with little to no advancement in patient outcome. Unfortunately, AML causes more than 10,000 deaths a year in the U.S. alone.
Researchers now believe that successful AML treatments will require personalized plans based upon patients’ individual biological profiles.